Scarica l'app Stockscreener
18.81
2.13%
-0.41
Dopo l'orario di chiusura:
19.12
0.31
+1.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$19.22
Aprire:
$19.99
Volume 24 ore:
2.07M
Relative Volume:
0.77
Capitalizzazione di mercato:
$14.58B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-13.02
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
-0.58%
1M Prestazione:
+24.49%
6M Prestazione:
-19.41%
1 anno Prestazione:
+13.04%
Intervallo 1D:
$18.75
$20.09
Intervallo di 1 settimana:
$18.38
$20.09
Portata 52W:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.81 | 14.90B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
SUMMIT THERAPEUTICS INC BIG TRADING SWING | SMMT STOCK Simply Click The Next Internet Page (JHLdCFn8fQ) - Mshale
Citigroup starts coverage of Summit Therapeutics Inc (SMMT), Apr 08 2026, Buy - Meyka
What's Going On With Summit Therapeutics Stock Wednesday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
$Summit Therapeutics (SMMT.US)$ - Moomoo
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Bu - gurufocus.com
Pullback Watch: Is Summit Therapeutics Inc forming higher highs and higher lowsQuarterly Portfolio Review & Low Drawdown Investment Ideas - baoquankhu1.vn
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Buy' Rating | SMMT Stock News - GuruFocus
Aug Selloffs: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Market Review & High Accuracy Swing Trade Signals - baoquankhu1.vn
Stifel Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $45 - Moomoo
Sentiment Recap: Does Summit Therapeutics Inc have a sustainable dividendInsider Buying & Expert Curated Trade Ideas - baoquankhu1.vn
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - MSN
Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) asks shareholders to approve 8M-share Plan increase - Stock Titan
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN
Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo
Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com
(SMMT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Summit plunges 80 percent after muscle-wasting disorder drug fails - AOL.com
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - MSN
Barclays Remains a Hold on Summit Therapeutics (SMMT) - The Globe and Mail
Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo
Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm
Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - finance.yahoo.com
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance
Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider
Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - marketscreener.com
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire
Summit lung cancer drug showed 10.1-month brain PFS in Phase III - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - MarketBeat
What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey
Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn
5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's
Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - marketbeat.com
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Why Summit Therapeutics Stock Is Suddenly Surging - TipRanks
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):